These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34327467)

  • 1. C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV.
    Nelson AJ; Puri R; Brennan DM; Anderson TJ; Cho L; Ballantyne CM; Kastelein JJ; Koenig W; Kassahun H; Somaratne RM; Wasserman SM; Nissen SE; Nicholls SJ
    Am J Prev Cardiol; 2020 Sep; 3():100091. PubMed ID: 34327467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
    Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
    JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
    Puri R; Nissen SE; Somaratne R; Cho L; Kastelein JJ; Ballantyne CM; Koenig W; Anderson TJ; Yang J; Kassahun H; Wasserman SM; Scott R; Borgman M; Nicholls SJ
    Am Heart J; 2016 Jun; 176():83-92. PubMed ID: 27264224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
    Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Evolocumab on Coronary Plaque Composition.
    Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJP; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Honda S; Shishikura D; Scherer DJ; Borgman M; Brennan DM; Wolski K; Nissen SE
    J Am Coll Cardiol; 2018 Oct; 72(17):2012-2021. PubMed ID: 30336824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.
    Nicholls SJ; Kataoka Y; Nissen SE; Prati F; Windecker S; Puri R; Hucko T; Aradi D; Herrman JR; Hermanides RS; Wang B; Wang H; Butters J; Di Giovanni G; Jones S; Pompili G; Psaltis PJ
    JACC Cardiovasc Imaging; 2022 Jul; 15(7):1308-1321. PubMed ID: 35431172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HbA1c, Coronary atheroma progression and cardiovascular outcomes.
    Dykun I; Bayturan O; Carlo J; Nissen SE; Kapadia SR; Tuzcu EM; Nicholls SJ; Puri R
    Am J Prev Cardiol; 2022 Mar; 9():100317. PubMed ID: 35112095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN.
    Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    JACC Cardiovasc Imaging; 2014 Oct; 7(10):1013-22. PubMed ID: 25240453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of GLAGOV study.
    Nicholls SJ; Puri R
    Curr Opin Lipidol; 2017 Dec; 28(6):465-469. PubMed ID: 28937411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PCSK9 and Coronary Artery Plaque-New Opportunity or Red Herring?
    Barbieri L; Tumminello G; Fichtner I; Corsini A; Santos RD; Carugo S; Ruscica M
    Curr Atheroscler Rep; 2024 Oct; 26(10):589-602. PubMed ID: 39150672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between Circulating Baseline Proprotein Convertase Subtilisin Kexin Type 9 Levels and Efficacy of Evolocumab.
    Desai NR; Giugliano RP; Wasserman SM; Gibbs JP; Liu T; Scott R; Sabatine MS
    JAMA Cardiol; 2017 May; 2(5):556-560. PubMed ID: 28122070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome.
    Yano H; Horinaka S; Ishimitsu T
    J Cardiol; 2020 Mar; 75(3):289-295. PubMed ID: 31495548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy.
    Puri R; Nissen SE; Shao M; Uno K; Kataoka Y; Kapadia SR; Tuzcu EM; Nicholls SJ
    Am J Cardiol; 2014 Nov; 114(10):1465-72. PubMed ID: 25282317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-reactive protein and coronary atheroma regression following statin therapy: A meta-regression of randomized controlled trials.
    Gao D; Hua R; Jiesisibieke D; Ma Y; Li C; Wu S; Ma Q; Xie W
    Front Cardiovasc Med; 2022; 9():989527. PubMed ID: 36440015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors underlying regression of coronary atheroma with potent statin therapy.
    Puri R; Nissen SE; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; St John J; Wolski K; Uno K; Kataoka Y; Nicholls SJ
    Eur Heart J; 2013 Jun; 34(24):1818-25. PubMed ID: 23644179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors regress coronary atherosclerotic plaque? A systematic review and meta-analysis.
    Wu Z; Gao L; Lin Z
    Am J Transl Res; 2023; 15(1):452-465. PubMed ID: 36777825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of evolocumab on the progression and stability of atherosclerotic plaques as evaluated by grayscale and iMAP-IVUS.
    Kong Q; Liu M; Li Y; Zhu Q; Su G
    Ann Palliat Med; 2020 Sep; 9(5):3078-3088. PubMed ID: 33065780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data.
    Qamar A; Giugliano RP; Keech AC; Kuder JF; Murphy SA; Kurtz CE; Wasserman SM; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2019 Jan; 4(1):59-63. PubMed ID: 30540337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.
    Giugliano RP; Pedersen TR; Saver JL; Sever PS; Keech AC; Bohula EA; Murphy SA; Wasserman SM; Honarpour N; Wang H; Lira Pineda A; Sabatine MS;
    Stroke; 2020 May; 51(5):1546-1554. PubMed ID: 32312223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial.
    Zanchin C; Koskinas KC; Ueki Y; Losdat S; Häner JD; Bär S; Otsuka T; Inderkum A; Jensen MRJ; Lonborg J; Fahrni G; Ondracek AS; Daemen J; van Geuns RJ; Iglesias JF; Matter CM; Spirk D; Juni P; Mach F; Heg D; Engstrom T; Lang I; Windecker S; Räber L
    Am Heart J; 2021 Aug; 238():33-44. PubMed ID: 33951415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.